◀ Back to CXCL1

CXCL1 — DPP4

Text-mined interactions from Literome

Takekoshi et al., Mol Cancer Ther 2012 (Lung Neoplasms...) : In vitro analysis of amino-terminal cleavage by enzymes dipeptidylpeptidase IV ( DPPIV/CD26 ) and matrix metalloproteinase-2 (MMP-2) resulted in 25-fold and 2-fold slower degradation rates, respectively, of CXCL122 compared with wtCXCL12
Eriksson et al., Scand J Rheumatol 2013 (Arthritis, Rheumatoid) : Two weeks after infliximab infusion, CXCL10/IP-10 , CCL2/MCP-1, and CCL4/MIP-1ß had decreased significantly ( p = 0.005, 0.037, and 0.028, respectively ), and after 30 weeks of treatment, soluble CD26 was significantly increased ( p = 0.050 )